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Background: Hand foot and mouth disease (HFMD) is a disease of public health importance across the Asia-Pacific
region. The disease is caused by enteroviruses (EVs), in particular enterovirus A71 (EV-A71). In EV-A71-associated
HFMD, the infection is sometimes associated with severe manifestations including neurological involvement and
fatal outcome. The availability of a robust diagnostic assay to distinguish EV-A71 from other EVs is important for
patient management and outbreak response.
Methods: We developed and validated an internally controlled one-step single-tube real-time RT-PCR in terms of
sensitivity, linearity, precision, and specificity for simultaneous detection of EVs and EV-A71. Subsequently, the assay
was then applied on throat and rectal swabs sampled from 434 HFMD patients.
Results: The assay was evaluated using both plasmid DNA and viral RNA and has shown to be reproducible with a
maximum assay variation of 4.41 % and sensitive with a limit of detection less than 10 copies of target template
per reaction, while cross-reactivity with other EV serotypes was not observed. When compared against a published
VP1 nested RT-PCR using 112 diagnostic throat and rectal swabs from 112 children with a clinical diagnosis of HFMD
during 2014, the multiplex assay had a higher sensitivity and 100 % concordance with sequencing results which
showed EVs in 77/112 (68.8 %) and EV-A71 in 7/112 (6.3 %). When applied to clinical diagnostics for 322 children, the
assay detected EVs in throat swabs of 257/322 (79.8 %) of which EV-A71 was detected in 36/322 (11.2 %) children. The
detection rate increased to 93.5 % (301/322) and 13.4 % (43/322) for EVs and EV-A71, respectively, when rectal swabs
from 65 throat-negative children were further analyzed.
Conclusion: We have successfully developed and validated a sensitive internally controlled multiplex assay for rapid
detection of EVs and EV-A71, which is useful for clinical management and outbreak control of HFMD.
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Hand foot and mouth disease (HFMD) is a commonly
benign and self-limiting viral infection of infants and
young children worldwide. The disease is caused by
acute infection with Enterovirus A of the family Picorna-
viridae including coxsackievirus A6 (CV-A6), CV-A10,
CV-A16, and enterovirus A71 (EV-A71) [1–5]. However,
in contrast to the common mild patterns of previous
sporadic epidemics, since 1997 fulminant outbreaks of
HFMD involving millions of children with neurological
involvement and sometimes fatal cardiopulmonary com-
plications have occurred across the Asia-Pacific region
with EV-A71 being the most frequent pathogen isolated
from patients with clinical complications and fatal cases
[6–9]. Despite the public health burden of (EV-A71-
associated) HFMD, currently, no clinically proven effective
antiviral agents or vaccines are available for routine use.
The availability of a rapid, high-throughput and accur-
ate diagnostic assay that can simultaneously detect and
distinguish between EVs and EV-A71 is an ideal aid to
patient management and may help outbreak response
with regards to predicting the possible level of severity
of the outbreak and thereby initiating appropriate public
health interventions. Although EVs/EV-A71 diagnosis
can be achieved by virus isolation, cell culture based
methods are time-consuming and insensitive [10]. Mo-
lecular assays based on specific amplification viral nu-
cleic acids, in particular real-time PCR, are sensitive,
specific and high-throughput and are therefore methodsTable 1 Virus isolate and origin/source
Strain Serotypes Species Subgeno-group
9522 EV-A71 A C1
8 M/6/99 EV-A71 A C2
001-KOR-00 EV-A71 A C3
VN152 EV-A71 A C4
VN5559 EV-A71 A C4
VN5784 EV-A71 A C5
13903 EV-A71 A B3
A10/4 EV-A71 A B4
18431 EV-A71 A B5
H08214350 CV-A4 A NA
H07314334 CV-A16 A NA
H06418058 CV-A21 C NA
H06474277 E-6 B NA
H08306574 E-30 B NA
H05062273 CV-B5 B NA
Gdula CV-A6 A NA
Texas 12 CV-A12 A NA
G-14 CV-A14 A NA
Note: aPublic Health England, UK, bAmerican Type Culture Collection, NA: Not availaof choice [11, 12]. Herein, we describe the development
and validation of an internally controlled single-step
multiplex real-time RT-PCR for simultaneous detection
of EVs and EV-A71 in clinical specimens from patients
with HFMD.
Results
Analytical specificity and 95 % LLOD
The analytical specificity of the assay was evaluated on
extracted RNA derived from EV strains belonging to 9
different EV serotypes and isolates belonging to 8 differ-
ent (sub)genogroups of EV-A71 (Table 1). The fluores-
cent signal of the EV probe was detected from all
reactions containing viral RNA extracted from diverse
EV serotypes belonging to different species including A
(including EV-A71), B and C, whereas the signal of the
EV-A71 probe was detected only from reactions contain-
ing viral RNA extracted from EV-A71 of all 8 tested sub-
genogroups, but not from other EV A-C types.
The analytical sensitivity (95 % LLOD) of the assay was
evaluated using both plasmid DNA and EV-A71 RNA.
The detection limit of the assay for EVs and EV-A71 was
7.1 and 5.3 copies of plasmid DNA per reaction, and was
2.9 and 1.1 TCID50 (equivalent to 9.1 and 3.2 cDNA
copies per reaction, respectively) of EV-A71, respectively.
Linearity and precision
The linearity of the multiplex assay was calculated from
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DNA and viral RNA was 0.993 and 0.995, and 0.996 and
0.995 for the EV and EV-A71, respectively (Figs. 1 and 2).
The precision of the assay was assessed by measuring
variations within (intra-assay variation) and between runs
(inter-assay variation) at high, medium, and low concen-
trations of template. The maximum intra- and inter-assay
variations using plasmid DNA and viral RNA were 3.12 %
and 4.41 %, respectively (Table 2).
Comparison with nested RT-PCR and sequencing
confirmation
To assess the clinical specificity of the assay, a subset of
112 swabs (45 throat and 67 rectal swabs from 112 chil-
dren with clinically suspected HFMD) was randomly se-
lected for comparison with a published nested RT-PCR
assay [13]. Among 102 specimens positive for EVs using
multiplex real-time RT-PCR, 21 were not detected by
the nested RT-PCR assay, while none of the 10 multiplex
RT-PCR negative specimens were positive by the nested
RT-PCR assay (Table 3). Further confirmation for the ac-
curacy of the multiplex RT-PCR results was achieved by
sequencing of amplified products generated by the VP1
assay. Of the 81 nested RT-PCR positive specimens, VP1
sequences were successfully obtained from 75 (71 non-A
B
Fig. 1 Linearity of the multiplex RT-PCR assay using 10-fold dilution
series of plasmid DNA containing the PCR templates of EV (a) and
EV-A71 (b), Cp = crossing pointEV-A71 and 4 EV-A71). Sequence analyses revealed that
all 71 viruses detected by the EVs generic primers/probe
but not by the EV-A71 assay belonged to 11 different
EV serotypes of which CV-A6 accounted for 60 %,
whereas all 4 EV-A71 positive specimens detected by the
multiplex assay were confirmed as EV-A71 (Fig. 3).
Assay application in clinical studies
The assay was applied in clinical samples (rectal and
throat swabs) obtained from 322 children enrolled in
our on-going HFMD research program. Multiplex RT-
PCR analysis of throat swab specimens revealed an over-
all detection rate of 79.8 % (257/322) for EVs, of which
EV-A71 was detected in 11.2 % (36/322). Further diag-
nostic effort on rectal-swab specimens from 65/322
(20.2 %) children whose throat swabs were negative by
the multiplex assay showed that 44/65 (56.9 %) rectal
swabs were EVs positive, of which 7(10.8 %) were EV-A71.
No virus was detected in 21 paired throat and rectal
swabs, corresponding to 6.5 %. Thus, the overall detection
rates of EVs and EV-A71 in 322 clinically suspected
HFMD children were 93.5 % (301/322) and 13.4 % (43/
322), respectively.
Discussion
We have successfully developed and validated a single-
tube multiplex one-step real-time RT-PCR for high-
throughput, sensitive, and specific detection of EVs and
EV-A71 in clinical samples. The performance of the
assay is internally controlled by adding an optimal
amount of EAV to the tested specimens allowing for
quality assessment of the whole procedure from nucleic
acid extraction to amplification. Furthermore, this assay
is rapid (turnaround time of less than 3 h), cost-effective
(reagent associated cost of $ 8 per sample) and resource
efficient (both EVs and EV-A71 are tested simultan-
eously) and is therefore useful for clinical management
and outbreak response of HFMD.
Although primers and probes used in this study were
derived from previous studies [8, 14, 15], different re-
porters and quenchers were selected and combined to
ensure efficiency of assay performance (i.e. no cross-
fluorescence). In addition, because when combined with
the new reporter (Cy5) and quencher (BHQ3), the ori-
ginal EVs probe [14] produced a high baseline signal.
The sequence of the EVs probe was therefore changed
into its reverse complement to reduce high baseline
signal (data not shown), while maintaining sensitivity
and specificity as shown by the outcome of the specifi-
city experiments.
We originally developed the EV-A71 assay that was
successfully used for diagnosis of HFMD caused by EV-
A71 in previous studies [8] and during the outbreak of
severe HFMD in Cambodia in 2012 [16]. However, this
AB
Fig. 2 Linearity of the multiplex RT-PCR assay using 10-fold dilution series of RNA extracted from an EV-A71 isolate; EV (a) and EV-A71 (b), Cp:
crossing point. Concentration used were equivalent to 3 × 101 to 3 × 106 cDNA copies per reaction for EV and 3 × 100 to 3 × 106 cDNA copies per
reaction for EV-A71
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genogroups C4 and C5 that were circulating at that time
[8, 16]. Our recent assessment of EV-A71 sequences
available in the GenBank suggested that modification by
incorporation degenerated bases in the primer sequences
was required to ensure a detection of all EV-A71 subge-
nogroups (Additional file 1: Figure S1). Indeed, the EV-
A71 assay with modified primers was able to detect
EV-A71 isolates of subgenotypes B3–B5 and C1–C5Table 2 Maximum intra and inter assay variations in different conce
Concentration Plasmid DNA (c
4 × 106
Maximum EV assay co-variation Intra-assay 0.53
Inter-assay 3.13
Maximum EV-A71 assay co-variation Intra-assay 0.52
Inter-assay 3.19that have been circulating in the Asia-Pacific region,
while maintaining specificity. Although the assay has
not been evaluated for subgenotypes B1 and B2, in
silico analysis showed that the primers and probes used
in this assay would enable their detection (Additional
file 1: Figure S1).
The multiplex RT-PCR assay has been fully evaluated
in terms of linearity, analytical sensitivity, precision and
specificity. When evaluated on a wide range of templatentrations of plasmid DNA and viral RNA
opies) Viral RNA (TCID50)
4 × 103 4 × 101 9.6 × 105 9.6 × 103 9.6 × 101
0.93 1.37 1.49 0.84 0.77
1.36 2.18 4.41 3.01 2.54
1.00 2.18 1.34 0.73 0.73
1.37 1.85 2.66 1.56 1.53
Table 3 Comparison with VP1 nested RT-PCR and serotype
confirmation by sequencing
Tests Multiplex real-time RT-PCR Total
(n)EVs positive EVs negative
Non-EV-A71 EV-A71
Nested RT-PCR Positive (n) 77 4 0 81
Negative (n) 18 3 10 31
Total (n) 95 7 10 112
VP1 sequencing (n) 71 4 0 75
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ity, thus fulfilling the requirements of a clinical diagnostic
molecular assay [17]. The 95 % LLOD was less than 10
copies RNA/DNA per reaction, and thereby compliant
with MIQE (Minimum Information for publication of
Quantitative real-time PCR Experiments) guidelines [18].
All tested EV serotypes, representing a broad range of
types belonging to EV A-C were detected by the EVs
generic PCR, which is in accordance with the published
report [14]. The EV-A71 primer-probe was specific for
EV-A71 viruses since cross-reactivity with other EV se-
rotypes was not observed when the assay was tested on
cultured isolates of different non-EV-A71 serotypes.
The assay performance was further compared against
a VP1 nested RT-PCR by testing both assay performance
on 112 rectal and throat swabs from 112 children with
HFMD. The VP1 nested RT-PCR was selected as an
assay for comparison because: 1) it can function as a
‘reference’ assay for assessment of our assay performance
in terms of both sensitivity and specificity as it also al-
lows for serotype determination of HFMD pathogens byFig. 3 Pie chart showing the frequency of specific EV serotypes detected b
(n = 45), CV-A 10 (15), CV-A 16 (3), EV-A71 (4), CV-A 8 (1), CV-A 7 (1), CV-A 5sequencing of the obtained PCR amplicon [13], 2) it is a
WHO recommended assay for diagnostics of HFMD pa-
tients [19], and 3) it has been widely implemented in
diagnostic laboratories [20, 21]. In these clinical speci-
mens, the assay described here was more sensitive than
the VP1 nested RT-PCR. Indeed, the multiplex RT-PCR
could detect the presence of EVs RNA in 102 specimens
as compared to 81 by the nested one. In addition, the
specificity of the diagnostic result was confirmed by VP1
sequencing of 71 specimens that were non-EV-A71 PCR
positive and 4 EV-A71 positive specimens, which further
confirms our initial sequence analyses including BLAST
and sequence alignment comparison (data not shown)
that showed not potential cross reactivity of EV-A71
assay with other EV serotypes.
Following our proposed diagnostic workflow, the assay
was applied on samples from 322 children enrolled to
our on-going HFMD studies between May and Septem-
ber 2014. Using throat swab alone for initial diagnosis,
80 % (257/322) of the children had EVs/EV-A71 de-
tected in throat swabs. The detection rate increased with
13.5 % (i.e. an overall diagnostic rate of 93.5 % (301/322)
was achieved) when rectal swabs from 65 patients who
had a negative throat swab test were further analyzed,
indicating that the use of throat swab alone would result
in false negative results for a substantial proportion of
cases.
It is worth to note that throat and rectal swabs have
been used for diagnostics of HFMD patients, although
throat swab is more sensitive by virus isolation [19, 22].
However, parallel testing of both throat and rectal swabs
would not be cost-effective. Therefore, following oury nested RT-PCR followed by sequencing of amplified products; CV-A6
(1), CV-A 4 (1), CV-B2 (1), CV-B5 (1), E-30 (1), PV2 [vaccine strain] (1)
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was maximized, while maintaining cost-effectiveness (i.e.
only 20 % of the rectal swabs needed to be tested), and
retaining the usefulness of throat swabs for subsequent
analyses (such as virus isolation [22]).
Although detection and differentiation of EV-A71 can
be achieved with the existing real-time RT-PCR assays
[11, 12, 14, 23–29], some of these assays are not multi-
plexed, targeting either EVs [14, 29] or EV-A71 [12, 24,
26, 27] separately. Multiplex RT-PCRs for EV-A71 and
other EVs have been recently developed [11, 23, 25, 28].
However, these assays did not include internal controls
[11, 25, 28] or were not fully validated in terms sensitiv-
ity, linearity, precision, and specificity. Although a com-
parison of our assay with other published methods is
desirable, the absence of a true gold standard limits the
usefulness of this. It should however be noted that the
95 % LLOD of our assay was less than 10 copies per re-
action, in agreement with MIQE guidelines (as men-
tioned above) and within the detection limit ranges of
between 5 and 90 copies per reaction of those previously
published assays. Our paper represents another option
for internally controlled rapid and simultaneous detec-
tion of EVs and EV-A71.
Conclusions
We have successfully developed and validated a single-
tube multiplex one-step real-time RT-PCR for high-
throughput, sensitive, and specific detection of EVs and
EV-A71 in clinical samples, which can be a great aid to




Diagnostic throat and rectal swab specimens used in this
study were collected prospectively from 434 children
with a clinical diagnosis of HFMD presenting or admit-











Note: FAM=Carboxyfluorescein; Cy5= Cyanine 5; Cyan500 = Cyan 500 NHS ester; BHQ=Ho Chi Minh City: Hospital for tropical Diseases (HTD)
and Children’s Hospital 1 (CH1) and 2 (CH2), between
May and September 2014. Swabs were collected in viral
transport medium, divided into three aliquots and stored
at -80 °C until analysis.Virus isolates
An EV-A71 subgenogroup C4 isolate from a child with
HFMD admitted to HTD during the 2011 outbreak and
17 other different isolates belonging to different EV-A71
subgenogroups and non-EV-A71 serotypes obtained
from the Department of Biomedical Science, University
of Malaya, Malaysia, Public Health England, UK and
American Type Culture Collection, USA were used for
assay validation (Table 1).
Infective titers of 50 % tissue culture infectious doses
(TCID50) were titrated on human rhabdomyosarcoma
cells using a standard method [22]. The concentration of
viral stock was converted to cDNA copies per μl by the
multiplex real-time RT-PCR assay with plasmid DNA
serving as standard control.
Equine Arteritis Virus (EAV) was used as an in-
ternal control and was prepared as described previ-
ously [15, 30]. The concentration of internal control
virus was selected using RT-PCR analysis of serial
tenfold dilutions and the amount of virus used in
the PCR assay had expected crossing point (Cp) values of
between 30 and 33 [15, 30].Primers and probes
Primers and probes for EVs, EV-A71 and EAV assays
used in this study were adapted from previous studies
[8, 14, 15, 31] with slight modifications and are listed in
Table 4. Briefly, for the EVs assay, the original probe was
replaced by its reverse-complement. Modification of
EV-A71 primers and probe was done by incorporation of
degenerate bases to allow detection of all known subgeno-
types of EV-A71.gle reaction
Final concentration Note
400 nM Internal control [15]
400 nM
100 nM
400 nM Enterovirus specific primers and probe [14]
400 nM
200 nM
400 nM Enterovirus 71 specific primers and probe [8]
400 nM
40 nM
black hole quencher; R = A and G; Y = T and C; V =A, C, and G; D =A, G, and T
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Viral RNA was extracted from clinical specimens and
culture materials using the QIAamp Viral RNA Mini kit
(QIAgen GmbH, Hilden, Germany). In brief, 140 μl of
culture supernatant/throat/rectal swabs in viral transport
medium was first mixed with 20 μl of EAV and total nu-
cleic acid was then extracted according to the manufac-
turer’s instruction, eluted in 100 μl elution buffer and
stored at -80 °C until used.
Real-time RT-PCR was done using the SuperScriptR III
One-Step qRT-PCR System with PlatinumR Taq DNA
Polymerase (Invitrogen, Carlsbad, CA, USA) and was
performed in a LightCycler 480 II machine (Roche Diag-
nostics GmbH, Mannheim, Germany). The reaction was
performed in a final volume of 25 μl containing 12.5 μl
2X RT-PCR reaction Mix, primers and probes at appro-
priate concentrations (Table 4), 0.5 μl Enzyme Mix, and
2 μl viral RNA or plasmid DNA. The cycling conditions
included one cycle of 60 °C for 3 min, followed by
15 min at 53 °C and 2 min at 95 °C, and 45 cycles of
15 s at 95 °C, 1 min at 53 °C (including fluorescence ac-
quisition) and 15 s at 72 °C.Preparation of plasmid controls
Amplified PCR products generated by RT-PCR amplifica-
tion of viral RNA derived from an EV-A71 subgenogroup
C4 isolate mentioned above utilizing EV and EV-A71 spe-
cific primers (Table 1) were purified and cloned into a pCR
2.1-TOPO plasmid using the pCR 2.1-TOPO TA Cloning
kit (Invitrogen), following the manufacturer’s instruction.
Constructed plasmid containing amplified product was
purified using the QIAprep Spin Miniprep Kit (Qiagen).
Plasmid concentration was determined by NanoDrop
spectrometer (Thermo-Scientific, Loughborough, UK).
An equal amount of plasmids containing the cloned EV
and EV-A71 target genes was mixed together and stored
at -80 °C until analysis.Fig. 4 A flow chart showing the work-flow diagnosis. Note: +ve =
positive; -ve = negative # Rectal swab analysis only when patients
had throat-swab PCR negative *The analysis ended when rectal
swab PCR is completedLower limit of 95 % detection, linearity and precision
Analytical evaluation of the multiplex assay was done as
previously described [17, 18] using both plasmid DNA
controls and extracted RNA from an EV-A71 isolate
(VN152, Table 1).
To obtain the lower limit of 95 % detection (95 %
LLOD), the mixed EV/EV-A71 plasmid DNA controls
were serially diluted two-fold to obtain a series of con-
centrations ranging from 20 copies/μl to 0.6 copies/μl.
Dilution series of extracted viral RNA from an EV-A71
virus with concentrations ranging from 0.3-9.6 TCID50/μl
equivalent to 0.9 – 30.1 cDNA copies/μl were used. The
experiment was performed on these dilution series once a
day on five consecutive days with 10 replicates for each
concentration. The 95 % LLOD was estimated using theProbit regression model in SPSS 19 (SPSS Inc, NY, USA)
as described previously [15].
The linearity was assessed by performing the assay on
10-fold serial dilutions of plasmid DNA controls (ranging
from 108 to 101 copies/μl) or EV-A71 RNA (ranging from
9.6 × 105 to 9.6 TCID50 /μl equivalent to 3.1 × 10
6 to 30.1
cDNA copies/μl). For each material, the experiment was
carried out in a single run with 5 replicates for each dilu-
tion point. Linearity was calculated using linear regression
analysis in Microsoft Excel and a range of input with an
R2 value of 0.99 was accepted.
The precision was determined using both plasmid
DNA and viral RNA controls at high, intermediate and
low concentrations. The experiments were performed daily
on five consecutive days in quintuplicate for each concen-
tration. The intra- and inter-assay variability were calcu-
lated by assessing the Cp value deviation.Assay interpretation
The procedure was monitored by including an optimal
amount of EAV (Cp value between 30 and 33) function-
ing as internal control for nucleic acid extraction and
amplification steps. A sample was considered positive if
negative controls were negative and the tested sample
was positive with a Cp value equal to or less than 40. A
sample was considered negative if negative controls were
negative, positive controls were positive with Cp values
of about 30 and internal control showed a positive result
with a Cp value between 30 and 33. A result was consid-
ered as inconclusive if negative controls were positive
and/or the internal control showed a result outside of
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for EVs/EV-A71 [30].Nested RT-PCR, sequencing and sequence analysis
The nested RT-PCR targeting viral protein 1 (VP1) gene
sequence was carried out as previously described [13],
and served as a reference for evaluation of the multiplex
RT-PCR as there is currently no gold standard assay for
diagnosis of HFMD. For this purpose, 112 clinical speci-
mens (45 throat and 67 rectal swabs from 112 children)
were used. Sequencing of VP1 PCR products was done
using the BigDye Terminator V3.1 Cycle Sequencing kit
in an ABI 3130XL DNA sequencer (Applied Biosystems,
Carlsbad, CA, USA). The sequences were assembled
using ContigExpress software - a component of Vector
NTI Suit 7 (Informax Inc., NY, USA). Viral serotype was
determined as described previously [13], e.g. by BLASTing
the obtained sequences against the sequence available in
GenBank.Assay application
The assay was applied on clinical samples obtained from
322 children with clinically suspected HFMD enrolled to
our ongoing HFMD research program. The analysis was
carried out using the diagnostic work-flow as described
in Fig. 4, which includes an initial screening for EVs/EV-
A71 in throat swabs and, to maximize the yield of the
detection, rectal swabs from children who had a negative
throat swab (Fig. 4) was further tested.Ethical approval
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reviewed and approved by the local Institutional Review
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